VOI - Voice of Indonesia | RRI - Radio Republik Indonesia

Israel and Morocco agreed on Thursday to normalize relations in a deal brokered with U.S. help, making Morocco the fourth Arab country to set aside hostilities with Israel in the past four months.

It joins the United Arab Emirates, Bahrain and Sudan in beginning to forge deals with Israel, driven in part by U.S.-led efforts to present a united front against Iran and roll back Tehran’s regional influence.

In a departure from longstanding U.S. policy, President Donald Trump agreed as part of the deal to recognize Morocco’s sovereignty over the Western Sahara, a desert region where a decades-old territorial dispute has pitted Morocco against the Algeria-backed Polisario Front, a breakaway movement that seeks to establish an independent state.

President-elect Joe Biden, due to succeed Trump on Jan. 20, will face a decision whether to accept the U.S. deal on the Western Sahara, which no other Western nation has done. A Biden spokesman declined to comment.

While Biden is expected to move U.S. foreign policy away from Trump’s “America First” posture, the Democrat has indicated he will continue the pursuit of what Trump calls “the Abraham Accords” between Israel and Arab and Muslim nations.

Trump sealed the Israel-Morocco accord in a phone call with Morocco’s King Mohammed VI on Thursday, the White House said.

“Another HISTORIC breakthrough today! Our two GREAT friends Israel and the Kingdom of Morocco have agreed to full diplomatic relations – a massive breakthrough for peace in the Middle East!” Trump wrote on Twitter.

Mohammed told Trump that Morocco intends to facilitate direct flights for Israeli tourists to and from Morocco, according to a statement from Morocco’s royal court.

“This will be a very warm peace. Peace has never - the light of peace on this Hanukkah day has never - shone brighter than today in the Middle East,” Israeli Prime Minister Benjamin Netanyahu said in a statement, referring to a Jewish eight-day holiday starting on Thursday night.

Palestinians have been critical of the normalization deals, saying Arab countries have set back the cause of peace by abandoning a longstanding demand that Israel give up land for a Palestinian state before it can receive recognition.

Egypt and UAE issued statements welcoming Morocco’s decision. Egypt and Israel signed a peace treaty in 1979.

“This step, a sovereign move, contributes to strengthening our common quest for stability, prosperity, and just and lasting peace in the region,” Abu Dhabi’s crown prince, Sheikh Mohammed bin Zayed al-Nahyan, wrote on Twitter.

But Senator Jim Inhofe, the Republican chairman of the U.S. Senate’s Armed Services Committee, denounced Trump’s “shocking and deeply disappointing” decision to recognize Morocco’s sovereignty over Western Sahara. Inhofe said people living in the area should vote in a referendum to decide their future.

“The president has been poorly advised by his team. He could have made this deal without trading the rights of a voiceless people,” Inhofe said in a statement.

A senior U.S. official said Trump knew about Inhofe’s opposition to recognizing Morocco’s sovereignty over Western Sahara. But Inhofe’s argument lost ground with the president when the senator refused to hold up the annual defense spending bill when Trump demanded it be used to repeal a law granting liability protection to tech companies, the official said.

The Morocco deal could be among the last that Trump’s team, led by White House senior adviser Jared Kushner and U.S. envoy Avi Berkowitz, will negotiate before giving way to Biden’s incoming administration.

Kushner told reporters on a conference call it was inevitable that Saudi Arabia would eventually strike a similar deal with Israel. A U.S. official said the Saudis were not likely to act until after Biden takes office, and even then there would be strong internal opposition that could block such a move in the near term. (Reuters)

Some of the rooms in Korea Superfreeze Inc’s coldest warehouse are so frigid that a cup of warm water thrown into one will immediately turn into snow.

Located 65 km (40 miles) below Seoul and boasting temperatures frostier than an Antarctic winter, the facility would be the best, perhaps only, place in South Korea suitable for bulk storage of Pfizer’s COVID-19 vaccine, says company CEO Kim Jin-ha.

“As soon as we heard about the Pfizer vaccine, we started getting ready... other options wouldn’t work,” Kim told Reuters, adding that the warehouse’s use of liquefied natural gas (LNG) to keep temperatures cool trumped electricity.

Warehouses which use electricity would have difficulty maintaining the -70 degrees Celsius (-94 F) required by the vaccine for storage and carry the risk of the temperature rising during a power blackout, he said.

The company, which is backed by Goldman Sachs and SK Holdings Co Ltd, has been in talks with the Korea Disease Control and Prevention Agency since early November and while nothing is yet decided, expectations are high it will land a contract.

The agency has asked Korea Superfreeze to provide plans and cost estimates for storing and distributing vaccines, including how it would handle a scenario where vaccines would be shipped to 260 different locations, Kim said.

South Korea has arranged to buy 20 million doses of the vaccine developed by Pfizer and its German partner BioNTech.

The country also has deals for 20 million doses each for the vaccines developed by Moderna Inc and AstraZeneca Plc/Oxford University and for another 4 million doses from Johnson & Johnson.

In total, that would be enough to inoculate 34 million people in a country of 51.8 million and shipments are expected to begin no later than March.

Kim said, however, it was not clear to him if the agency would tap the company for vaccines other than Pfizer’s which have less onerous cold storage requirements. Moderna’s vaccine can be stored for up to six months at -20 C while AstraZeneca’s vaccine needs only normal fridge temperatures.

To accommodate Pfizer’s vaccine, Korea Superfreeze is planning a dedicated passageway and elevator so there is no interference from outside temperatures. Once it confirms it has a contract, it will begin construction which may take 2-3 months.

The warehouse also has 220 closed-circuit cameras that monitor resting cargo round the clock, Kim said.

He added that South Korea and Japan were the only countries with LNG-powered facilities which can offer storage at these temperatures and that the warehouses in Japan were much smaller and more remotely located due to earthquake risks.

All in all, the Korea Superfreeze rooms capable of storing goods at -70 C add up to 1,600 square metres (17,222 square feet). But just how much of that will be needed remains unclear as the company has not yet ascertained how big the containers carrying the vaccines will be and how much will be shipped to South Korea at a time.

Kim said, however, that some regular customers of the storage facilities might have to be inconvenienced.

“For the tuna and other goods that are being kept here at -60 degrees, we’re going to have to ask their permission, compensate them for it and clear them out of here.” (Reuters)

South Korea authorities scrambled on Thursday to build hospital beds in shipping containers to ease strains on medical facilities stretched by the latest coronavirus wave, which shows little sign of abating with 682 new cases.

The resurgence of infections has rekindled concerns about an acute shortage of hospital beds, prompting Seoul city to begin installing container beds for the first time since the start of the pandemic.

Health authorities plan to step up testing by launching temporary sites at some 150 locations across the greater Seoul area.

“We’re in a critical situation where our anti-virus efforts and medical system’s capacity could reach their limits before long,” Health Minister Park Neung-hoo told a meeting, vowing to mobilise all available resources.

“Above all, we will secure sufficient treatment centres and hospital beds for critical cases so that they can receive proper treatment in a timely manner.”

In Seoul, with a population of 10 million, only around 3% of hospital beds were available for severe cases, and 17% for all patients, according to Park Yoo-mi, a quarantine officer at the city government.

The city has dispatched 50 epidemiological investigators to 25 districts to help track down potential patients, in addition to 10 sent from the central government, Park said.

A total of 274 military and police officers and other administrative staff will also be mobilised for epidemiological surveys starting Friday, she added.

Thursday’s 682 new infections came a day after the daily tally hit 686, the second-highest since the country’s first case was confirmed in January, even as tougher social distancing rules took effect this week, according to the Korea Disease Control and Prevention Agency (KDCA).

New cases have been persistently around 600 over the past week, driven by smaller, harder-to-trace clusters around the densely populated capital city of Seoul, whereas the early two waves were centred on a handful of groups or regions.

The governor of South Korea’s most populous province Gyeonggi, with 13.5 million people, said on Wednesday he plans to conduct mass testing in some areas to discover potential cases.

President Moon Jae-in called for buying more COVID-19 vaccines after authorities announced deals with four global drugmakers as part of a drive to inoculate 44 million people, or 60% of the country’s population.

Total infections rose to 40,098, with 564 deaths, KDCA data showed. (Reuters)

Britain’s medicine regulator said anyone with a history of anaphylaxis to a medicine or food should not get the Pfizer-BioNTech COVID-19 vaccine, giving fuller guidance on an earlier allergy warning about the shot.

Starting with the elderly and frontline workers, Britain began mass vaccinating its population on Tuesday, part of a global drive that poses one of the biggest logistical challenges in peacetime history.

The Medicines and Healthcare Products Regulatory Agency (MHRA) said there had been two reports of anaphylaxis and one report of a possible allergic reaction since the rollout began.

“Any person with a history of anaphylaxis to a vaccine, medicine, or food should not receive the Pfizer BioNTech vaccine,” MHRA Chief Executive June Raine said in a statement.

“Most people will not get anaphylaxis and the benefits in protecting people against COVID-19 outweigh the risks... You can be completely confident that this vaccine has met the MHRA’s robust standards of safety, quality, and effectiveness.”

Anaphylaxis is an overreaction of the body’s immune system, which the National Health Service describes as severe and sometimes life-threatening.

The fuller guidance, clarifying that the main risk was from anaphylaxis specifically, was issued after consulting experts on allergies. The MHRA had initially advised anyone with a history of a “significant allergic reaction” not to take the shot.

Pfizer and BioNTech said they were supporting the MHRA’s investigation.

Last week, Britain’s MHRA became the first in the world to approve the vaccine, developed by Germany’s BioNTech and Pfizer, while the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) continue to assess the data.

A top U.S. official said on Wednesday that Americans with known severe allergic reactions may not be candidates for Pfizer’s COVID-19 vaccine until more was understood about what had happened.

Canada’s health ministry said it would look at the reported adverse reactions in Britain, but said adverse events were to be expected and would not necessarily change the risk/benefit of the shot after the country approved the vaccine.

ALLERGIC REACTION

MHRA chief Raine told lawmakers such allergic reactions had not been a feature of the Pfizer’s clinical trials.

Pfizer has said people with a history of severe adverse allergic reactions to vaccines or the candidate’s ingredients were excluded from their late stage trials, which is reflected in the MHRA’s emergency approval protocol.

However, the allergic reactions may have been caused by a component of Pfizer’s vaccine called polyethylene glycol, or PEG, which helps stabilise the shot and is not in other types of vaccines.

Imperial College London’s Paul Turner, an expert in allergy and immunology, who has been advising the MHRA on their revised guidance, told Reuters: “As we’ve had more information through, the initial concern that maybe it affects everyone with allergies is not true.”

“The ingredients like PEG which we think might be responsible for the reactions are not related to things which can cause food allergy. Likewise, people with a known allergy to just one medicine should not be at risk,” Turner told Reuters.

The EMA said in an email that all quality, safety and efficacy data would be taken into account in assessing the vaccine, including data generated outside the EU.

In the United States, the FDA released documents on Tuesday in preparation for an advisory committee meeting on Thursday, saying the Pfizer vaccine’s efficacy and safety data met its expectations for authorization.

The briefing documents said 0.63% of people in the vaccine group and 0.51% in the placebo group reported possible allergic reactions in trials, which Peter Openshaw, professor of experimental medicine at Imperial College London, said was a very small number.

“The fact that we know so soon about these two allergic reactions and that the regulator has acted on this to issue precautionary advice shows that this monitoring system is working well,” he said.

However, Gregory Poland, a virologist and vaccine researcher with the Mayo Clinic in Rochester, Minnesota, said that the MHRA and NHS had overreacted initially.

“I would not have broadened to the degree they did,” he said.

“It’s reasonable to let the world know about this, and to be aware of it in terms of people who have had reactions like this to vaccines. I think to say medicines, foods or any other allergies is past the boundary of science.” (Reuters)